While associations between iLBP expression and prognosis or therapeutic response have been consistently reported across tumour cohorts [73,74,75,76,77,83,91,92,93,94,100,101,102,103,104,105,117,118,119,120,121,122,123], these remain largely retrospective or bioinformatics-based analyses, and prospective clinical validation is required before their use as biomarkers can be translated into routine clinical practice. This evidence concerns the gene FABP6 and neoplasm.